Ottobock stock backs Blue Arbor's 10.5 million US-dollar round

Ottobock stock is linked to a strategic investment in next-generation prosthetic control after Blue Arbor Technologies announced a 10.5 million US-dollar Series A financing on October 28, 2026. Business Wire reported that Ottobock led the round as Blue Arbor's strategic partner.

Blue Arbor will use the proceeds to complete feasibility studies and pursue an Investigational Device Exemption from the U.S. Food and Drug Administration for clinical studies of the RESTORE External Sensing Unit. The company will also begin development of the fully implantable RESTORE Internal Sensing Unit.

RESTORE moves toward clinical studies

The RESTORE Neuromuscular Interface System is designed to enable independent and simultaneous control of a prosthesis' fingers, wrist and elbow. Blue Arbor is developing both a wearable external sensing interface and an implantable version that connects with the same platform.

Blue Arbor said feasibility work was highlighted by a successful second-in-human procedure using the external sensing unit at the Medical University of Vienna. The company said two human implantations had been completed. Professor Oskar Aszmann, director of the university's Center for Bionic Extremity Reconstruction, said patients had adapted quickly and naturally to the technology, according to the financing announcement.

Strategic investment broadens exposure

Ottobock CEO Oliver Jakobi said the investment complements the group's core business and offers long-term growth potential. The financing gives Ottobock a strategic role in a technology platform that is still in clinical and regulatory development rather than commercial distribution.

The RESTORE system has received FDA Breakthrough Device Designation and has been accepted into the FDA's Total Product Life Cycle Advisory Program pilot. Blue Arbor also said the system was selected for a University of Michigan clinical study funded by a National Institutes of Health UG3 grant. That study is intended to compare surface electrodes with implanted electrodes for prosthetic control.

Ottobock stock traded at 48.40 euros on Lang & Schwarz at 10:59:45 CEST on Friday, October 30, 2026. The real-time quote of Ottobock stock shows the current trading level.

German equities remained the relevant market setting for investors assessing new corporate developments; current DAX market coverage provides the broader index context.

More news and analyses on Ottobock stock will track further clinical, regulatory and financing developments around the RESTORE platform.